Soluble immune checkpoints in cancer: production, function and biological significance

Immune checkpoints play important roles in immune regulation, and blocking immune checkpoints on the cell membrane is a promising strategy in the treatment of cancer. Based on this, monoclonal antibodies are having much rapid development, such as those against CTLA-4 (cytotoxic T lymphocyte antigen 4) and PD-1 (programmed cell death protein 1).But the cost of preparation of monoclonal antibodies is too high and the therapeutic effect is still under restrictions. Recently, a series of soluble immune checkpoints have been found such as sCTLA-4 (soluble CTLA-4) and sPD-1 (soluble PD-1). They are functional parts of membrane immune checkpoints produced in different ways and can be secreted by immune cells. Moreover, these soluble checkpoints can diffuse in the serum. Much evidence has demonstrated that these soluble checkpoints are involved in positive or negative immune regulation and that changes in their plasma levels affect the development, prognosis and treatment of cancer. Since they are endogenous molecules, they will not induce immunological rejection in human beings, which might make up for the deficiencies of monoclonal antibodies and enhance the utility value of these molecules. Therefore, there is an increasing need for investigating novel soluble checkpoints and their functions, and it is promising to develop relevant therapies in the future. In this review, we describe the production mechanisms and functions of various soluble immune checkpoint receptors and ligands and discuss their biological significance in regard to biomarkers, potential candidate drugs, therapeutic targets, and other topics.

• Publication year

  2018

• Venue

  Journal of Immunotherapy for Cancer

• Publication date

  2018-11-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/s40425-018-0449-0PMID 30482248PMCID 6260693
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predictive Value of Soluble Programmed Death-1 for Severe Sepsis and Septic Shock During the First Week in an Intensive Care Unit

  2019cited by this paper
• Soluble programmed death-1 ligand 1(sPD-L1) is significantly reduced in the serum of type 1 diabetes patients

  2018cited by this paper
• Increased Soluble CD137 Levels and CD4+ T‐Cell‐Associated Expression of CD137 in Acute Atherothrombotic Stroke

  2018cited by this paper
• High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma

  2018cited by this paper
• Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small‐cell Lung Cancer

  2018cited by this paper
• Early Detection of Hepatocellular Carcinoma in Patients with Hepatocirrhosis by Soluble B7-H3

  2017cited by this paper
• Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis

  2017cited by this paper
• New checkpoints in cancer immunotherapy

  2017cited by this paper
• Reduced sB7-H3 Expression in the Peripheral Blood of Systemic Lupus Erythematosus Patients

  2017cited by this paper
• Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

  2017cited by this paper
• Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma

  2017cited by this paper
• Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients.

  2017cited by this paper
• The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

  2016cited by this paper
• PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma

  2016cited by this paper
• Immune checkpoint inhibitors for cancer treatment

  2016cited by this paper
• Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib.

  2016cited by this paper
• Soluble Programmed Death 1 (PD-1) Is Decreased in Patients With Immune Thrombocytopenia (ITP)

  2016cited by this paper
• CTLA-4 and PD-1 Pathways

  2016cited by this paper
• Role of soluble programmed death-1 (sPD-1) and sPD-ligand 1 in patients with cystic echinococcosis.

  2016cited by this paper
• Upregulation of soluble B7-H3 in NSCLC-derived malignant pleural effusion: A potential diagnostic biomarker correlated with NSCLC staging.

  2016cited by this paper
• Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma

  2016cited by this paper
• Soluble B7-H3 promotes the invasion and metastasis of pancreatic carcinoma cells through the TLR4/NF-κB pathway

  2016cited by this paper
• Advances in Cancer Immunotherapy in Solid Tumors

  2016cited by this paper
• Soluble programmed cell death receptor-1 (sPD-1): a potential biomarker with anti-inflammatory properties in human and experimental acute respiratory distress syndrome (ARDS)

  2016cited by this paper
• Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes

  2016cited by this paper
• Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

  2016cited by this paper
• Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment.

  2016cited by this paper
• Abstract 4058: Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism

  2015cited by this paper
• Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma

  2015cited by this paper
• The future of immune checkpoint therapy

  2015cited by this paper
• Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells

  2015cited by this paper
• [Levels of programmed death-1 and programmed death ligand-1 in the peripheral blood of patients with oral squamous cell carcinoma and its clinical implications].

  2015cited by this paper
• Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells

  2015cited by this paper
• Circulating Programmed Death-1 as a Marker for Sustained High Hepatitis B Viral Load and Risk of Hepatocellular Carcinoma

  2014cited by this paper
• Clinical Significance of Serum Soluble T Cell Regulatory Molecules in Clear Cell Renal Cell Carcinoma

  2014cited by this paper
• Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?

  2014cited by this paper
• A Soluble Form of CD80 Enhances Antitumor Immunity by Neutralizing Programmed Death Ligand-1 and Simultaneously Providing Costimulation

  2014cited by this paper
• A role for the TIM‐3/GAL‐9/BAT3 pathway in determining the clinical phenotype of multiple sclerosis

  2014cited by this paper
• Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications.

  2014cited by this paper
• Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels

  2014cited by this paper
• Clinical significance of the induction of macrophage differentiation by the costimulatory molecule B7-H3 in human non-small cell lung cancer

  2014cited by this paper
• B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients

  2014cited by this paper
• High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

  2014cited by this paper
• Clinical implications of elevated serum soluble CD137 levels in patients with acute coronary syndrome

  2013cited by this paper
• The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production

  2013cited by this paper
• Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response.

  2013cited by this paper
• Novel antibodies targeting immune regulatory checkpoints for cancer therapy

  2013cited by this paper
• Clinical significance of the induction of macrophage differentiation by the costimulatory molecule B7-H3 in human non-small cell lung cancer

  2013cited by this paper
• The soluble isoform of CTLA‐4 as a regulator of T‐cell responses

  2013cited by this paper
• Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1–Mediated Immune Suppression

  2013cited by this paper
• Characterization of a Soluble B7-H3 (sB7-H3) Spliced from the Intron and Analysis of sB7-H3 in the Sera of Patients with Hepatocellular Carcinoma

  2013cited by this paper
• Aberrant production of soluble inducible T-cell co-stimulator (sICOS) and soluble programmed cell death protein 1 (sPD-1) in patients with chronic hepatitis C.

  2013cited by this paper
• In Vivo Blockade of the Programmed Cell Death-1 Pathway Using Soluble Recombinant PD-1-Fc Enhances CD4+ and CD8+ T Cell Responses but Has Limited Clinical Benefit

  2013cited by this paper
• Increased PD-1 on CD4(+)CD28(-) T cell and soluble PD-1 ligand-1 in patients with T2DM: association with atherosclerotic macrovascular diseases.

  2013cited by this paper
• Expression of Programmed Death-1 (PD-1) on CD4+ and CD8+ T cells in Rheumatoid Arthritis

  2013cited by this paper
• A Soluble Form of CTLA-4 Is Present in Paediatric Patients with Acute Lymphoblastic Leukaemia and Correlates with CD1d+ Expression

  2012cited by this paper
• Enhancement of Membrane B7-H3 Costimulatory Molecule but Reduction of Its Soluble Form in Multiple Sclerosis

  2012cited by this paper
• Reconstructed adeno-associated virus with the extracellular domain of murine PD-1 induces antitumor immunity.

  2012cited by this paper
• Potential role of soluble B7‐H3 in liver immunopathogenesis during chronic HBV infection

  2012cited by this paper
• Admission levels of soluble CD137 are increased in patients with acute pancreatitis and are associated with subsequent complications.

  2012cited by this paper
• Soluble B7-H1: differences in production between dendritic cells and T cells.

  2012cited by this paper
• SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line.

  2012cited by this paper
• Increased production of circulating soluble co-stimulatory molecules CTLA-4, CD28 and CD80 in patients with rheumatoid arthritis.

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma

  2011cited by this paper
• Detection and quantitation of soluble B7-H3 in expressed prostatic secretions: a novel marker in patients with chronic prostatitis.

  2011cited by this paper
• The Soluble CTLA-4 Splice Variant Protects From Type 1 Diabetes and Potentiates Regulatory T-Cell Function

  2011cited by this paper
• Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines.

  2011cited by this paper
• Enhancement of Vaccine-induced Primary and Memory CD8+ T-cell Responses by Soluble PD-1

  2011cited by this paper
• Aberrant production of soluble co-stimulatory molecules CTLA-4 and CD28 in patients with chronic hepatitis B.

  2011cited by this paper
• B7-H3 Augments the Inflammatory Response and Is Associated with Human Sepsis

  2010cited by this paper
• Regulating immunity and inhibiting tumor growth by the recombinant peptide sPD-1-CH50.

  2009cited by this paper
• Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity

  2009cited by this paper
• Soluble PD-1 is Associated with Aberrant Regulation of T Cells Activation in Aplastic Anemia

  2009cited by this paper
• CD137, implications in immunity and potential for therapy.

  2009cited by this paper
• Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.

  2008cited by this paper
• Investigation on the effects of soluble programmed death-1 (sPD-1) enhancing anti-tumor immune response

  2008cited by this paper
• Effects of retinoic acid on the β-catenin/TCF pathway in culture porcine tracheobronchial epithelial cells

  2008cited by this paper
• Soluble CD276 (B7‐H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum

  2008cited by this paper
• Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)

  2007cited by this paper
• Soluble PD-1 Facilitates 4-1BBL–Triggered Antitumor Immunity against Murine H22 Hepatocarcinoma In vivo

  2007cited by this paper
• Comment on “Aberrant Regulation of Synovial T Cell Activation by Soluble Costimulatory Molecules in Rheumatoid Arthritis”

  2007cited by this paper
• Response to Comment on “Aberrant Regulation of Synovial T Cell Activation by Soluble Costimulatory Molecules in Rheumatoid Arthritis”

  2007cited by this paper
• Human Soluble CD80 is Generated by Alternative Splicing, and Recombinant Soluble CD80 Binds to CD28 and CD152 Influencing T‐cell Activation

  2007cited by this paper
• Regular paper on-line at: www.actabp.pl Purification and characterization of GlcNAc-6-P 2-epimerase from Escherichia coli K92

  2007cited by this paper
• Aberrant Regulation of Synovial T Cell Activation by Soluble Costimulatory Molecules in Rheumatoid Arthritis1

  2006cited by this paper
• Contribution of the PD‐1 ligands/PD‐1 signaling pathway to dendritic cell‐mediated CD4+ T cell activation

  2006cited by this paper
• HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD‐1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma

  2006cited by this paper
• Levels of the soluble forms of CD80, CD86, and CD83 are elevated in the synovial fluid of rheumatoid arthritis patients.

  2006cited by this paper
• In vitro co-stimulation of anti-tumor activity by soluble B7 molecules.

  2006cited by this paper
• Circulating levels and clinical significance of soluble CD86 in myeloma patients

  2006cited by this paper
• Expression of CD137 and CD137 ligand in colorectal cancer patients.

  2006cited by this paper
• A molecular perspective of CTLA-4 function.

  2006cited by this paper
• Plasma concentrations of soluble CTLA‐4, CD28, CD80 and CD86 costimulatory molecules reflect disease severity of acute asthma in children

  2006cited by this paper
• Triple Combination of Oncolytic Herpes Simplex Virus-1 Vectors Armed with Interleukin-12, Interleukin-18, or Soluble B7-1 Results in Enhanced Antitumor Efficacy

  2006cited by this paper
• Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma.

  2005cited by this paper
• Combination B7-Fc Fusion Protein Treatment and Treg Cell Depletion Therapy

  2005cited by this paper
• Alternative splice variants of the human PD-1 gene.

  2005cited by this paper
• Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus.

  2005cited by this paper
• Levels of soluble CD137 are enhanced in sera of leukemia and lymphoma patients and are strongly associated with chronic lymphocytic leukemia

  2005cited by this paper

• Soluble immune checkpoint proteins as predictive biomarkers for lymph node metastases in penile cancer

  2026cites this paper
• Soluble Mediators Related to Immunity in Pregnancy‐Related Disorders: Roles of Immune Checkpoints, Platelet Activation Markers, TNF Receptors, and NETs

  2026cites this paper
• DNA-peptide complex as bivalent and multifunctional probe: Ultra-sensitive and specific detection of sPD-L1 in serum

  2026cites this paper
• Towards precise and real-time immunodiagnostics through electrochemical sensing of immune checkpoint proteins

  2026cites this paper
• Hybrid membrane-camouflaged nanomedicines for precision oncology: rational design, mechanism innovation, and diversified applications

  2026cites this paper
• Soluble immune checkpoints reflect immune activation and treatment response in high-risk systemic sclerosis patients treated with plasma exchange.

  2026cites this paper
• Plasma levels of soluble PD-1, TIM-3, LAG-3 and galectin-3 and the degree of liver fibrosis in CHC and the impact of successful antiviral treatment on their levels

  2025cites this paper
• Soluble immune checkpoints are dysregulated in patients with sickle cell disease and correlate with inflammatory mediators, autoantibodies, immune cell profiles, and clinical outcomes

  2025cites this paper
• Macrophage-derived IL-15 imprints peritoneal TRM-like CD8 T cells in cirrhosis and spontaneous bacterial peritonitis

  2025cites this paper
• Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer

  2025cites this paper
• Liquid biopsy for cancer immunotherapy: Biomarkers to predict and monitor response upon immune checkpoint blockade

  2025cites this paper
• Soluble biomarkers as predictors of response to immunotherapy in Non-Small Cell Lung cancer (NSCLC)-insights from the tumor microenvironment perspective

  2025cites this paper
• Investigation of immune checkpoint molecules (CTLA-4, PD-1, PD-L1, Tim-3) expressions in preeclampsia: A comparative study of membranous and soluble forms.

  2025cites this paper
• Soluble immune checkpoint landscape in sickle cell disease links systemic inflammation, autoimmunity, and pain

  2025cites this paper
• Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer

  2025cites this paper
• Genome-Wide Aggregated Trans Effects Analysis for Circulating Proteins Indicates a Key Role of Immune Checkpoints in Type 1 Diabetes

  2025cites this paper
• Soluble immune checkpoint factors reveal high-risk osteosarcoma subtypes and enable early metastasis prediction

  2025cites this paper
• Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy

  2025cites this paper
• Tumor immunology: unraveling the complex interaction between tumors and the immune system: a narrative review

  2025cites this paper
• PD-L1 splice variant-driven soluble PD-L1 secretion promotes immune evasion in gastric cancer.

  2025cites this paper
• Experimental Optimization of a Plasmonic Surface Biofunctionalization, toward the Bimodal Biosensing and Kinetic Characterization of sPD1

  2025cites this paper
• Immune checkpoint changes correlate with the progression and prognosis of amyotrophic lateral sclerosis

  2025cites this paper
• Clinical Significance of Elevated Levels of Soluble‐Form Immune Checkpoint Molecules in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma

  2025cites this paper
• Beyond the tumor: the gut microbiome as a key player in immunotherapy efficacy and resistance

  2025cites this paper
• Downregulated AhR Expression is Linked with Increased IFN-γ Production and Impaired Immune Checkpoint Upregulation in Vitiligo (MS# JID-2024-1072).

  2025cites this paper
• Co-regulation of miRNA and lncRNA on immunosuppression gene: unveiling the regulatory networks in cancer.

  2025cites this paper
• Prognostic and clinicopathological value of soluble programmed cell death ligand-1 (sPD-L1) in patients with peripheral T-cell lymphoma: a meta-analysis

  2025cites this paper
• Serum soluble Tim‑3 is elevated in patients with cervical cancer and is higher in advanced clinical stages

  2025cites this paper
• Targeting PD-L1 for PCNS-DLBCL: from molecular effects to clinical translation

  2025cites this paper
• Soluble immune checkpoint molecules: mechanism of formation, function, role in malignant neoplasms

  2025cites this paper
• Soluble Herpes Virus Entry Mediator and Type II/III Interferons Are Upregulated in Primary Biliary Cholangitis

  2025cites this paper
• Innate immune checkpoint SIRPα/CD47 blockade ameliorates silica-induced pulmonary fibrosis by modulating macrophage immunity.

  2025cites this paper
• Translation element EIF4A1 is a potential divergent immune biomarker between colon cancer and rectal cancer

  2025cites this paper
• Soluble B7 and TNF family in colorectal cancer: Serum level, prognostic and treatment value.

  2025cites this paper
• Discovery of core genes for systemic lupus erythematosus via genome-wide aggregated trans-effects analysis

  2025cites this paper
• Prognostic and clinicopathological role of soluble programmed cell death ligand-1 in patients with diffuse large B-cell lymphoma: a meta-analysis

  2025cites this paper
• Age-stratified circulating immune signatures reveal non-invasive biomarkers for colorectal cancer detection

  2025cites this paper
• Association of immune cells with the risk of basal cell carcinoma: A bidirectional Mendelian randomized study.

  2025cites this paper
• Soluble immune checkpoints in endometrial cancer – a discovery study

  2025cites this paper
• Unleashing the Power of immune Checkpoints: A new strategy for enhancing Treg cells depletion to boost antitumor immunity.

  2025cites this paper
• Genome‐Wide Aggregated Trans Effects Analysis Identifies Genes Encoding Immune Checkpoints as Core Genes for Rheumatoid Arthritis

  2025cites this paper
• Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis

  2025cites this paper
• The Society for Immunotherapy of Cancer Perspective on Liquid Biopsy and Radiomics Based Technologies for Immuno-Oncology Biomarker Discovery and Application.

  2025cites this paper
• A novel HVEM-Fc recombinant protein for lung cancer immunotherapy

  2025cites this paper
• Characterization of alternative sPD-1 isoforms reveals that ECD sPD-1 signature predicts an efficient antitumor response

  2025cites this paper
• Lymphocyte Inhibition Mechanisms and Immune Checkpoints in COVID-19: Insights into Prognostic Markers and Disease Severity

  2025cites this paper
• Plasma inflammatory and angiogenic protein profiling of patients with sickle cell disease

  2025influential citation
• Tipping the balance: the PD1-axis as modulator in chronic inflammatory demyelinating polyneuropathy.

  2025cites this paper
• Patients with peripheral artery disease demonstrate altered expression of soluble and membrane-bound immune checkpoints

  2025cites this paper
• Targeted degradation of sICOSL reverses cytotoxic T cells dysfunction

  2025cites this paper
• An observational study investigating soluble immune checkpoints as indicators of severe COVID-19

  2024cites this paper
• Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies

  2024cites this paper
• Machine learning models based on fluid immunoproteins that predict non-AIDS adverse events in people with HIV

  2024cites this paper
• Deciphering the role of alternative splicing in neoplastic diseases for immune-oncological therapies

  2024cites this paper
• The role of LOXL2 in tumor progression, immune response and cellular senescence: a comprehensive analysis

  2024cites this paper
• Strategies to optimize the promise of checkpoint-targeted anti-cancer therapy.

  2024cites this paper
• Poorly Differentiated Hepatocellular Carcinoma Cells Avoid Apoptosis by Interacting with T Cells via CD40-CD40L Linkage.

  2024cites this paper
• Peripheral Soluble Immune Checkpoint-Related Proteins Were Associated with Survival and Treatment Efficacy of Osteosarcoma Patients, a Cohort Study

  2024influential citation
• MicroRNAs and proteolytic cleavage of receptors in cancers: A comprehensive review of regulatory interactions and therapeutic implications

  2024cites this paper
• The immune checkpoint pathophysiology of depression and chronic fatigue syndrome due to preeclampsia: focus on sCD80 and sCTLA-4

  2024cites this paper
• The Influence of Drug-Eluting Beads Transarterial Chemoembolization on Serum Levels of Soluble Programmed Cell Death Protein-1 in Advanced Hepatocellular Carcinoma Patients

  2024cites this paper
• Soluble Plasma Proteins of Tumor Necrosis Factor and Immunoglobulin Superfamilies Reveal New Insights into Immune Regulation in People with HIV and Opioid Use Disorder

  2024cites this paper
• Plasma sPD-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination immunotherapy

  2024cites this paper
• Correlation between sCTLA-4 and sCD86 Levels with Disease Activity of Systemic Lupus Erythematosus (SLE) Patients Based on SLEDAI Score

  2024cites this paper
• Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade

  2024cites this paper
• Upregulation of PD-1 and its ligands and expansion of T peripheral helper cells in the nephritic kidneys of lupus-prone BXSB-Yaa mice

  2024cites this paper
• Soluble receptors in cancer: mechanisms, clinical significance, and therapeutic strategies

  2024cites this paper
• Progression of type 1 diabetes is associated with high levels of soluble PD-1 in islet autoantibody-positive children

  2024influential citation
• sCD163, sCD28, sCD80, and sCTLA-4 as soluble marker candidates for detecting immunosenescence

  2024influential citation
• Inflammasome complex genes with clinical relevance suggest potential as therapeutic targets for anti-tumor drugs in clear cell renal cell carcinoma

  2024cites this paper
• Sleep apnoea increases biomarkers of immune evasion, lymphangiogenesis and tumour cell aggressiveness in high-risk patients and those with established lung cancer

  2024cites this paper
• In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy

  2024cites this paper
• Soluble immune checkpoints associated with disease activity and treatment response in GD and TED.

  2024cites this paper
• T-cell and Soluble Co-inhibitory Receptor Expression in Patients With Visceral Leishmaniasis Are Markers of Treatment Response and Clinical Outcome

  2024cites this paper
• Alterations in circulating immunoregulatory proteins discriminate poor CD4 T lymphocyte trajectories in people with HIV on suppressive antiretroviral therapy

  2024cites this paper
• Distinct soluble immune checkpoint profiles characterize COVID-19 severity, mortality and SARS-CoV-2 variant infections

  2024cites this paper
• Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours

  2024cites this paper
• Role of β-adrenergic signaling and the NLRP3 inflammasome in chronic intermittent hypoxia-induced murine lung cancer progression

  2024cites this paper
• Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study

  2024cites this paper
• Dual-signal output biosensor for the detection of program death-ligand 1 and therapy progress monitoring of cancer.

  2024cites this paper
• Exploring the Role of PD-1 in the Autoimmune Response: Insights into Its Implication in Systemic Lupus Erythematosus

  2024cites this paper
• Release of Exosomal PD-L1 in Bone and Soft Tissue Sarcomas and Its Relationship to Radiotherapy

  2024cites this paper
• Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma

  2024cites this paper
• Persistently Elevated Expression of Systemic, Soluble Co-Inhibitory Immune Checkpoint Molecules in People Living with HIV before and One Year after Antiretroviral Therapy

  2024cites this paper
• AURKB promotes immunogenicity and immune infiltration in clear cell renal cell carcinoma

  2024cites this paper
• Soluble form of immune checkpoints in autoimmune diseases.

  2024cites this paper
• Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy

  2024cites this paper
• CD4+ T cell counts and soluble programmed death-1 at baseline correlated with hepatitis B surface antigen decline in HIV/HBV coinfection during combined antiretroviral therapy

  2023cites this paper
• The Role of Soluble Costimulatory Molecules as the Biomarkers for Aging Predictors

  2023influential citation
• Circulating immune checkpoints predict heart failure outcomes

  2023cites this paper
• The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions

  2023cites this paper
• Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy

  2023cites this paper
• Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3

  2023cites this paper
• Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression

  2023cites this paper
• Circulating Melanoma Cell Numbers Correlate with TIGIT-Positive Cytotoxic T Cell Counts in Advanced-Stage Melanoma Patients

  2023cites this paper
• Implications of LAG3 and CTLA4 immune checkpoints beyond PD-1/PD-L1 as a potential target in determining the prognosis of uveal melanoma patients

  2023cites this paper
• Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.

  2023cites this paper
• Prediction of risk and overall survival of pancreatic cancer from blood soluble immune checkpoint-related proteins

  2023cites this paper
• Upregulation of PD‐L1 by SARS‐CoV‐2 promotes immune evasion

  2023cites this paper
• Prognostic Value of Serum Soluble PD-L1 in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab

  2023cites this paper